Oppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target Keros Therapeutics (KROS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ...
Source LinkOppenheimer Initiates Keros Therapeutics at Outperform With $102 Price Target Keros Therapeutics (KROS) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ...
Source Link
Comments